1D
1M
3M
1Y
5Y
All
Price · Chart
Our own end-of-day closes
25 sessions
The line runs $181 on 11 June through $206.17 on 17 July, on a scale from $160 to $220. Days the market did not trade hold the previous close, flat.
Interactive IQV price chart by TradingView (requires JavaScript).
The chart above plots the price of IQV over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 25 sessions over that window: $181 on 11 June 2026 through $206.17 on 17 July 2026.
Market cap
$34.4B
52-week range
$157 – $244.30
Avg volume
350.8K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 9, 2026
About IQVIA Holdings Inc.
IQVIA Holdings, Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. Its offerings include analytics-driven clinical development, real-world data solutions, proprietary clinical and commercial applications, and a global healthcare IT infrastructure, all supported by a large proprietary health data set and advanced analytics. IQVIA serves clients such as biotech, pharmaceutical, and medical device companies, medical researchers, government agencies, and payers.
Company
Founded
2016
Headquarters
Durham
Exchange
NYSE
Sector
Healthcare
Class
Equity
Insiders Form 4
Filings 4 sets
IQV insider trades
SEC Form 4 · last 90 days · newest reported trade 2 Sep 2026
Open-market buys
0
Open-market sells
6
Net sold
$29.89M
Non-trade filings
4
Date
Insider
Type
Shares
Value
02 Sep 2026
Berkshire James G.
See Remarks
Sell
2,668
$697K
03 Aug 2026
STAUB W RICHARD
See Remarks
Sell
5,500
$1.28M
31 Jul 2026
Patel Bhavik
See Remarks
Sell
1,855
$436K
29 Jul 2026
BOUSBIB ARI
See Remarks
Sell
106,279
$26.09M
29 Jul 2026
Cherofsky Keriann
See Remarks
Sell
558
$137K
29 Jul 2026
Sherbet Eric
See Remarks
Sell
5,000
$1.25M
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Date
Insider
Type
Shares
Value
02 Sep 2026
Berkshire James G.
See Remarks
Option exercise
5,381
$709K
02 Sep 2026
Berkshire James G.
See Remarks
Other
2,713
$710K
29 Jul 2026
BOUSBIB ARI
See Remarks
Option exercise
156,206
$12.22M
29 Jul 2026
BOUSBIB ARI
See Remarks
Other
49,927
$12.22M
IQV reported financials
SEC EDGAR XBRL
IQV reported revenue of $16.3B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.4B.
Figure
Reported
Period
Revenue
$16.3B
31 Dec 2025
fiscal year
Net income
$1.4B
31 Dec 2025
fiscal year
Diluted EPS
$7.84
31 Dec 2025
fiscal year
Total assets
$29.7B
31 Mar 2026
at period end
Total equity
$6.2B
31 Mar 2026
at period end
Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026
IQV earnings
SEC EDGAR
Date
Period
EPS
Revenue
31 Mar 2026
Q1 2026
$1.61
—
31 Dec 2025
FY 2025
$7.84
—
30 Sep 2025
Q3 2025
$1.93
—
30 Jun 2025
Q2 2025
$1.54
—
31 Mar 2025
Q1 2025
$1.40
—
31 Dec 2024
FY 2024
$7.49
—
30 Sep 2024
Q3 2024
$1.55
—
30 Jun 2024
Q2 2024
$1.97
—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
12 of the 45 institutional funds we track reported a IQV position for the quarter ended 30 Jun 2026 — a combined $823.4M; the latest of those filings landed 02 Sep 2026.
Fund
Action
Shares
Value
Man Group
Added
+1,356.0% shares
295,679
$57.1M
Showing the 10 largest of 12 reported positions. The figures above count all of them.
Source: SEC EDGAR 13F filings
IQV fails-to-deliver
SEC CNS data
On 14 Aug 2026, 1 shares of IQV failed to deliver (about $242).
Settlement date
Shares failed
Notional
% of shares out
14 Aug 2026
1
$242
<0.001%
04 Aug 2026
17,170
$4.0M
0.010%
31 Jul 2026
450
$107K
<0.001%
29 Jul 2026
3
$729
<0.001%
Source: SEC fails-to-deliver (CNS) data